Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 4/20 | 0.51 |
| ▸ | RARB | P10826 | 4/20 | 0.51 |
| ▸ | RARG | P13631 | 4/20 | 0.51 |
| ▸ | RXRA | P19793 | 2/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.45 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HNF4A | P41235 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4641520 | 0.86 | MAP3K14 (0.42) | RARARARBRARGRXRACYP26A1 | |
| SCHEMBL27259563 | 0.82 | RARA (0.51) | RARARARBRARGRXRACYP26A1 | |
| SCHEMBL8982307 | 0.81 | NOTUM (0.49) | RARARARBRARGRXRAGAA | |
| SCHEMBL18211725 | 0.80 | MAP3K14 (0.50) | RARARARBRARGRXRACYP26A1 | |
| SCHEMBL30353228 | 0.80 | CYP3A4 (0.42) | GAAOPRM1OPRK1CYP3A4MAP3K14 | |
| SCHEMBL8293244 | 0.80 | RARA (0.49) | RARARARBRARGRXRACYP26A1 | |
| SCHEMBL9053722 | 0.79 | RARA (0.48) | RARARARBRARGRXRACYP26A1 | |
| SCHEMBL2599701 | 0.79 | RARA (0.48) | RARARARBRARGRXRACYP26A1 | |
| SCHEMBL29616597 | 0.79 | RARA (0.48) | RARARARBRARGRXRACYP26A1 | |
| SCHEMBL12188672 | 0.79 | AKR1B1 (0.57) | RARARARBRARGRXRACYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386506-B1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3390394-B1 | HYDANTOIN MODULATORS OF KV3 CHANNELS | AUTIFONY THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| US-20220071998-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-03-10 | — | — | US | disclosed |
| US-11180461-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-11147813-B2 | Modulators of KV3 channels to treat pain | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-10-19 | — | — | US | disclosed |
| EP-2852589-B1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-20200377485-A1 | HYDANTOIN MODULATORS OF KV3 CHANNELS | AUTIFONY THERAPEUTICS LTD (GB) | 2020-12-03 | — | — | US | disclosed |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY SRL (IT) | 2020-06-04 | — | — | US | disclosed |
| US-10611735-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| EP-3394061-B1 | 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME (US) | 2020-03-11 | — | — | EP | disclosed |
| WO-2017103604-A1 | HYDANTOIN MODULATORS OF KV3 CHANNELS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017098254-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20160318882-A1 | TRIAZOLES AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-11-03 | — | — | US | disclosed |
| US-20160318882-A1 | TRIAZOLES AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-11-03 | — | — | US | disclosed |
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| EP-0230475-B1 | NOVEL UREA DERIVATIVES, PROCESSES FOR PRODUCTION THEREOF AND HERBICIDE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4838924-A | NONPHYTOTOXIC | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611735-B2 | Triazoles as Kv3 inhibitors | KCNA3, KCNN3, KCNK3 | RARA 4557/4885RARB 4450/4885RARG 4489/4885 |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | RARA 4557/4885RARB 4450/4885RARG 4489/4885 |
| US-11147813-B2 | Modulators of KV3 channels to treat pain | KCNN3, KCNA3, KCND3 | RARA 4369/4885RARB 4204/4885RARG 4225/4885 |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | RARA 4557/4885RARB 4450/4885RARG 4489/4885 |
| US-20200377485-A1 | HYDANTOIN MODULATORS OF KV3 CHANNELS | KCNA3, KCNN3, KCND3 | RARA 4576/4885RARB 4489/4885RARG 4422/4885 |
| US-11180461-B2 | Triazoles as Kv3 inhibitors | KCNA3, KCNN3, KCNK3 | RARA 4557/4885RARB 4450/4885RARG 4489/4885 |
| US-20220071998-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | RARA 4372/4885RARB 4194/4885RARG 4223/4885 |
| US-20160318882-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | RARA 4557/4885RARB 4450/4885RARG 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.